Rituximab Therapy in Refractory Neuropsychiatric Lupus: Current Clinical Evidence

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 3, 2011, Pages 364-372

  Narváez, Javier ^a   Ríos Rodriguez, Valeria ^a   de la Fuente, Diana ^a   Estrada, Paula ^a   López Vives, Laura ^a   Gómez Vaquero, Carmen ^a   Nolla, Joan Miquel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Neuropsychiatric manifestations; Rituximab; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; CLONAZEPAM; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PREDNISONE; RITUXIMAB; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; FEMALE; HISPANIC; HUMAN; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL LITERATURE; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; OFF-LABEL USE; TREATMENT OUTCOME;

EID: 82955247822     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.06.004     Document Type: Article

References (32)

1. Unterman A., Nolte J.E., Boaz M., Abady M., Shoenfeld Y., Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2010 Oct 19, [Epub ahead of print].
2. Bertsias G.K., Boumpas D.T. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010, 6:358-367.
3. Sanna G., Bertolaccini M.L., Khamashta M.A. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008, 14:1261-1269.
4. Tieng A.T., Peeva E. B-cell-directed therapies in systemic lupus erythematosus. Semin Arthritis Rheum 2008, 38:218-227.
5. Ramos Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus. A systematic rfeview of off-label use in 188 cases. Lupus 2009, 18:767-776.
6. Murray E., Perry M. Off-label use of riyuximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010, 29:707-716.
7. Ye Y., Qian J., Gu Y., Chen X., Ye S. Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol 2011 Feb 23, [Epub ahead of print].
8. Galarza C., Valencia D., Tobón G.J., Zurita L., Mantilla R.D., Pineda Tamayo R., et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?. Clin Rev Allerg Immunol 2008, 34:124-128.
9. Terrier B., Amoura Z., Ravaud P., Hachulla E., Jouenne R., Combe B., et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2458-2466.
10. Catapano F., Chaudhry A.N., Jones R.B., Smith K.G., Jayne D.W. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 2010, 25:3586-3592.
11. Birnbaum J., Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008, 4:381-386.
12. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007, 66:470-475.
13. Tokunaga M., Fujii K., Saito K., Nakayamada S., Tsujimura S., Nawata M., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 2005, 44:176-182.
14. Saito K., Nawata M., Nakayamada S., Tokunaga M., Tsukada J., Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003, 12:798-800.
15. Saito K., Nawata M., Iwata S., Tokunaga M., Tanaka Y. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patients with active systemic lupus erythematosus. Rheumatology 2005, 44:1462-1464.
16. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007, 17:191-197.
17. Gottenberg J.E., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64:913-920.
18. Tamimoto Y., Horiuchi T., Tsukamoto H., Otsuka J., Mitoma H., Kimoto Y., et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evan's syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology 2008, 47:821-827.
19. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005, 44:1542-1545.
20. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007, 66:1259-1262.
21. Lu T.Y., Ng K.P., Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009, 61:482-487.
22. Armstrong D.J., McCarron M.T., Wright G.D. SLE-associated transverse myelitis successfully treated with rituximab (anti-CD20) monoclonal antibody. Rheumatol Int 2006, 26:771-772.
23. Jónsdóttir T., Gunnarsson I., Risselada A., Henriksson E.W., Klareskog L., Van Vollenhoven R.F. Treatment of refractory systemic lupus erythematosus with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008, 67:330-334.
24. Weide R., Heymanns J., Pandorf A., Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 2003, 12:779-782.
25. Smith K.G.C., Jones R.B., Burns S.M., Jayne D.R.W. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
26. Espinosa G., Mendizábal A., Minguez S., Ramo-Tello C., Capellades J., Olivé A., et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 2010, 39:246-256.
27. Nasir S., Kerr D.A., Birnbaum J. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 2009, 66:1160-1163.
28. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of ritxumab trial. Arthritis Rheum 2010, 62:222-233.
29. Furie R., Looney J., Rovin B., Latinis K., Appel G., Sanchez Guerrero J., et al. Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study [Abstract]. Ann Rheum Dis 2010, 69(Suppl 3):549.
30. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
31. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
32. Driver C.B., Ishimori M., Weisman M.H. The B cell in systemic lupus erythaematosus: a rational target for more effective therapy. Ann Rheum Dis 2008, 67:1374-1381.